Platelet activating factor (PAF) causes human platelet aggregation through the mechanism of membrane modulation.

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Prostaglandins Leukotrienes and Medicine

• Publication date

  1982-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0262-1746(82)90102-0PMID 6817343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• One, two, three or more pathways for platelet aggregation.

  2009cited by this paper
• Interaction of verapamil with human platelet alpha-adrenergic receptors.

  1982cited by this paper
• Effect of platelet-activating factor (PAF) on human platelets.

  1982cited by this paper
• Human platelet activation by an alkylacetyl analogue of phosphatidylcholine.

  1982cited by this paper
• 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) stimulates calcium influx in rabbit platelets.

  1981cited by this paper
• Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro.

  1981cited by this paper
• Rapid return of cyclo-oxygenase active platelets in dogs after a single oral dose of aspirin.

  1981cited by this paper
• Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with hermansky-Pudlak syndrome.

  1981cited by this paper
• Influence of alkyl ether chain length of acetyl glyceryl ether phosphorylcholine and its ethanolamine analog on biological activity toward rabbit platelets.

  1981cited by this paper
• Epinephrine potentiation of arachidonate‐induced aggregation of cyclooxygenase‐deficient platelets

  1981cited by this paper
• Modification of human platelet response to sodium arachidonate by membrane modulation.

  1981cited by this paper
• Low dose aspirin, platelet function and prostaglandin synthesis: influence of epinephrine and alpha adrenergic blockade.

  1981cited by this paper
• BACKGROUND AND PRESENT STATUS OF RESEARCH ON PLATELET‐ACTIVATING FACTOR (PAF‐ACETHER)

  1981cited by this paper
• Present concepts on the mechanisms of platelet aggregation.

  1981cited by this paper
• Characterization of alpha-adrenergic receptors in human platelets using [3H]clonidine.

  1981cited by this paper
• Characterization of alpha 2-adrenergic receptors on human platelets using [3H]yohimbine.

  1980cited by this paper
• Effects of 2,2'-dipyridyl and related compounds on platelet prostaglandin synthesis and platelet function.

  1980cited by this paper
• Influence of epinephrine on the aggregation response of aspirin-treated platelets.

  1980cited by this paper
• The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated plateletes.

  1980cited by this paper
• A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.

  1980cited by this paper
• Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog.

  1980cited by this paper
• Characterization of α2-adrenergic receptors on human platelets using [3H]yohimbine

  1980cited by this paper
• Thromboxanes: so what?

  1980cited by this paper
• Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine.

  1980cited by this paper
• Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs.

  1979cited by this paper
• Arachidonate-induced platelet aggregation in the dog.

  1979cited by this paper
• The lumi-aggregometer: a new instrument for simultaneous measurement of secretion and aggregation by platelets.

  1977cited by this paper
• Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets

  1977cited by this paper
• Activation of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. II. The role of serine proteases, cyclic nucleotides, and contractile elements in PAF-induced secretion

  1976cited by this paper
• Newborn Platelet Dysfunction: a Storage Pool and Release Defect

  1976cited by this paper
• Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency.

  1975cited by this paper
• Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

  1975cited by this paper
• Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction.

  1974cited by this paper
• A congenital defect in platelet prostaglandin production associated with impaired hemostasis in storage pool disease.

  1973cited by this paper
• Hereditary Defect in the Platelet Release Reaction Caused by a Deficiency in the Storage Pool of Platelet Adenine Nucleotides

  1970cited by this paper
• Role of Adenosine Diphosphate in the Aggregation of Human Blood-Platelets by Thrombin and by Fatty Acids

  1964cited by this paper
• MECHANISM OF PLATELET PLUG FORMATION AND ROLE OF ADENOSINE DIPHOSPHATE.

  1964cited by this paper

• Correlations among different platelet aggregation pathways in a group of healthy volunteers

  2024cites this paper
• New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19

  2020cites this paper
• Platelet Dysfunction in Type-2 Diabetes Mellitus

  2017cites this paper
• Platelet Activating Factor and Platelets

  1999cites this paper
• Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists.

  1986cites this paper
• Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions.

  1986cites this paper
• Synergistic responses in human platelets

  1986cites this paper
• Synergistic responses in human platelets. Comparison between aggregation, secretion and cytosolic Ca2+ concentration.

  1986cites this paper
• Studies on Mechanisms Involved in Hypoglycemia-Induced Platelet Activation

  1986cites this paper
• Action of platelet-activating factor on type 1 diabetic human platelets.

  1985cites this paper
• Role of arachidonic acid metabolism in human platelet activation and irreversible aggregation

  1985cites this paper
• Chapter 20. Platelet-Activating Factor: Multifaceted Biochemical and Physiological Mediator

  1985cites this paper
• Biologically active phospholipids as potential cardiovascular drugs

  1984cites this paper
• Chapter 4 – Platelet-activating factor

  1984cites this paper
• Penicillin induced human platelet dysfunction and its reversal by epinephrine.

  1983cites this paper